Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30results about How to "Inhibition of proliferative activity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Jaggedl agonist polypeptide and application thereof
InactiveCN104672313AInhibition of proliferative activityImprove survival ratePeptide/protein ingredientsDepsipeptidesMelanomaMedicine
The invention discloses a JaggedI agonist polypeptide and an application thereof, relates to the field of medicine and particularly relates to a polypeptide for promoting the combination of the JaggedI and the Notch and treating the malignant tumor. The sequence is a brand-new sequence of YSCTCPGDDSCPGFVGGGCKGKP. The proliferation of the melanoma cell and the liver cancer stem cell can be in vitro inhibited, the survival rate of the tumor-bearing mice in an in vivo test can be increased and a potential new drug development value can be realized.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Application of small interfering RNA in preparing medicament for treating colon cancer
InactiveCN101606948AInhibition of proliferative activityArrest growth cycleOrganic active ingredientsGenetic material ingredientsApoptosisColon cancer cell
The invention provides application of a small interfering RNA in preparing a medicament for treating colon cancer, wherein the small interfering RNA can inhibit the proliferation activity of colon cancer cells, retard the growth cycle of the colon cancer cells, induce the apoptosis of the colon cancer cells, and lower the activity of an mTOR / p70S6K / 4EBP1 signal channel of the colon cancer; besides, the small interfering RNA has therapeutic action on the transplantable tumor of nude mice colon cancer, and solves the technical problem that the prior art has poor curative effect and patient prognosis by adopting chemotherapy to treat middle and advanced stage colon cancer.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Application of cell cycle regulation gene fam114a2
ActiveCN107513556AInhibition of proliferative activityIncrease proliferative activityMicrobiological testing/measurementFermentationKidney cancerTreatment targets
The invention discloses an application of a cell cycle regulation gene fam114a2. A result of researches shows that the gene has a cell cycle regulating effect, and can inhibit cell proliferation, so the gene can be used as a cell cycle regulating reagent, and can be used as a tumor treatment target gene; and the gene is specifically highly-expressed in kidney cancer, liver cancer, stomach cancer and para-carcinoma tissues, so the gene can be used as a kidney cancer, liver cancer and stomach cancer diagnosis marker, and is of great significance to diagnosing and treating tumors.
Owner:SOUTHWEST UNIV
Pharmaceutical composition for treating large intestinal cancer
InactiveCN101292992AInhibition of proliferative activityGrowth inhibitionOrganic active ingredientsAntineoplastic agentsOncologyWilms' tumor
The invention discloses a drug composite for curing colorectal cancer. The drug composite is composed of 5-N deoxycytidine and rapamycin. The weight proportion of the 5-N deoxycytidine and the rapamycin is 66.7:1-249.6:1. Compared with the use of the 5-N deoxycytidine and the rapamycin separately for the treatment of the colorectal cancer, the invention can obviously inhibit the growth of human colorectal cancer cells and can significantly reduce the incidence rate and tumor size of colorectal cancer in rats.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Pharmaceutical combination containing rapamycin for treating large intestine cancer
InactiveCN101292980AInhibits the growth of human colorectal cancer cellsInhibition of proliferative activityOrganic active ingredientsAntineoplastic agentsLarge Intestine CancerDrug
The invention discloses a drug composite containing rapamycin for curing colorectal cancer. The drug composite is composed of PD98059 (2-amino-4-iso-oxygen flavone) and the rapamycin, the weight proportion of which is 292.4:1-1462:1. The invention can down regulate mTOR of colorectal cancer cells and the protein phosphorylation level of downstream p70s6K and 4E-BP1, so as to inhibit the proliferation activity of the colorectal cancer cells and simultaneously to block the growth cycle of the colorectal cancer cells, and then to inhibit the growth of human colorectal cancer cells and to reduce the incidence rate of the colorectal cancer and the tumor size in rats.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Angiostatin activating agent polypeptide and application thereof
InactiveCN104693281APromote hydrolysisPromote prohydrolysisPeptide/protein ingredientsPeptidesNew medicationsPharmaceutical drug
The invention relates to the field of drugs, in particular to polypeptide for activating angiostatin and treating malignant tumors. The sequence of the polypeptide is EALALMYYHSQSLRKTYP and is a brand new sequence. By means of the polypeptide, the angiostatin can be activated out of a body, proliferation of vascular endothelial cells can be suppressed, the tumor-bearing mice survival rate can be increased in an in-vivo test, and the potential new drug development value is achieved.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Phosphoramidate prodrug of nucleoside analogues, a pharmaceutical composition and applications of the phosphoramidate prodrug
PendingCN109535200AHas anti-hepatic fibrosis effectImprove liver fibrosisOrganic active ingredientsGroup 5/15 element organic compoundsTherapeutic effectTenofovir alafenamide
The invention relates to phosphoramidate prodrug of nucleoside analogues, or stereoisomers of the phosphoramidate prodrug, or a mixture of the stereoisomers of the phosphoramidate prodrug, or pharmaceutically acceptable salts or solvates of the phosphoramidate prodrug, and applications in the preparation of medicine for preventing or treating hepatitis B virus (HBV) and / or human immunodeficiency virus (HIV) infection alone or in combination with other medicine. The anti-HBV activity of the compound of the invention is equivalent to that of tenofovir alafenamide fumarate (TAF), and the compoundof the invention has the anti-liver fibrosis effect, can help improve the therapeutic effect of patients, and has good safety important clinical significance.
Owner:HANGZHOU HERTZ PHARMA
Signal-transducer-and-activator-of-transcription suppressing polypeptide and application thereof
InactiveCN104693280AInhibition of proliferative activityPrevention and Treatment of RelapsePeptide/protein ingredientsPeptidesNew medicationsPharmaceutical drug
The invention relates to the field of drugs, in particular to polypeptide for suppressing signal transducers and activators of transcription and preventing and treating recurrence and metastasis of a breast cancer after an operation is carried out. The sequence of the polypeptide is QLKNLYKDEANPSWPPTEQ and is a brand new sequence. By means of the polypeptide, proliferation and migration of breast cancer cells can be suppressed out of a body, the tumor-bearing mice survival rate can be increased in an in-vivo test, and the potential new drug development value is achieved.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Hydrolysis plasminogen polypeptide and application thereof
InactiveCN104694521AInhibition of proliferative activityImprove survival ratePeptide/protein ingredientsHydrolasesDrugFibrin
The invention discloses a hydrolysis plasminogen polypeptide and an application thereof, relates to the field of medicine, and in particular to the polypeptide capable of promoting plasminogen to hydrolyze to be angiostatin and capable of curing cancer. The sequence EMQKTVDRLKALNHFDENMW of the polypeptide is a brand new sequence. The plasminogen can be promoted to hydrolyze outside a mice body, vascular endothelial cells are restrained to proliferate, the survival rate of tumor-bearing mice can be improved in vivo test, and the hydrolysis plasminogen polypeptide and the application thereof have potential developing value for the new medicine.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Angiostatin activating agent polypeptide and application thereof
InactiveCN104693283AInhibition of proliferative activityImprove survival ratePeptide/protein ingredientsPeptidesMolecular biologyCancer research
The invention relates to the field of drugs, in particular to a polypeptide having functions of activating angiostatin and treating malignant tumor. The sequence of the polypeptide is a novel sequence of DEQWLMYPLFHSGLF, and the polypeptide can activate angiostatin in vitro, restrain vascular endothelial cells from proliferating, and improve the survival rate of tumor-bearing mice in vivo tests, thereby having potential development values of new drugs.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Fibroblast growth factor inhibiting polypeptide and application thereof
InactiveCN104725486AGood curative effectInhibition of proliferative activityPeptide/protein ingredientsDepsipeptidesFibre cellColon cancer cell
The invention relates to a fibroblast growth factor inhibiting polypeptide and an application thereof, and relates to the field of medicines, in particular to a polypeptide with the functions of inhibiting the fibroblast growth factor and treating malignant tumors. A sequence of the polypeptide is GVESEYELFMCYDDSTDVLVVVQIKC and is a bran-new sequence. The polypeptide is capable of inhibiting proliferation of colon cancer cells and hepatoma carcinoma cells in a body and improving the survival rate of tumor-bearing mice in an in vivo test, and has potential new medicine development value.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Hydrolysis plasminogen polypeptide and application thereof
InactiveCN104726438APromote hydrolysisInhibition of proliferative activityPeptide/protein ingredientsAntineoplastic agentsProfibrinolysinZymogen
The invention relates to the field of medicines, in particular to a polypeptide with the functions of promoting plasminogen to be hydrolyzed into angiostatin and treating malignant tumors. A sequence of the plasminogen polypeptide is THELGHLSQKLYGKRSN and is a bran-new sequence. The plasminogen polypeptide is capable of promoting the hydrolysis of the plasminogen in vitro, inhibiting proliferation of vascular endothelial cells, and improving the survival rate of tumor-bearing mice in an in vivo test, and has potential new medicine development value.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Fibroblast growth factor inhibitory polypeptide and application thereof
InactiveCN104693287AInhibition of proliferative activityImprove survival ratePeptide/protein ingredientsBiological material analysisAbnormal tissue growthFactor ii
The invention discloses fibroblast growth factor inhibitory polypeptide and an application thereof, and relates to the field of drugs, in particular to the polypeptide capable of restraining fibroblast growth factors and treating malignant tumors. The sequence is PSHNPEEQLSWGDSGEDSEPLP which is a branch-new sequence. The inhibitory polypeptide can restrain the proliferation of colonic cancer cells and hepatoma cells in vitro, the survival rate of tumor-bearing mice can be increased in vivo tests, and potential development value of new drugs can be achieved.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Fibroblast growth factor inhibiting polypeptides and application thereof
InactiveCN104693288AGood curative effectInhibition of proliferative activityPeptide/protein ingredientsBiological material analysisDrug developmentFibre cell
The invention discloses a fibroblast growth factor inhibiting polypeptides and application thereof, and relates to the field of medicines, in particular to polypeptides with a fibroblast growth factor inhibiting function and used for treating a malignant tumor. The sequence is GMLGGQEMWSWKCLLFWLKRRNFWQG and is a bran-new sequence, the polypeptides can inhibit proliferation of colon cancer cells and hepatoma cells in vitro and increase the survival rate of tumor-bearing mice in in-vivo tests and has potential new drug development value.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Application of small interfering RNA in preparing medicament for treating colon cancer
InactiveCN101606948BInhibition of proliferative activityArrest growth cycleOrganic active ingredientsGenetic material ingredientsApoptosisColon cancer cell
The invention provides application of a small interfering RNA in preparing a medicament for treating colon cancer, wherein the small interfering RNA can inhibit the proliferation activity of colon cancer cells, retard the growth cycle of the colon cancer cells, induce the apoptosis of the colon cancer cells, and lower the activity of an mTOR / p70S6K / 4EBP1 signal channel of the colon cancer; besides, the small interfering RNA has therapeutic action on the transplantable tumor of nude mice colon cancer, and solves the technical problem that the prior art has poor curative effect and patient prognosis by adopting chemotherapy to treat middle and advanced stage colon cancer.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
IL-2-induced T cell kinase stimulant polypeptide and use thereof
InactiveCN106478782AInhibition of proliferative activityInhibit migrationPeptide/protein ingredientsDepsipeptidesPancreas CancersStimulant
The invention relates to the field of drugs and concretely relates to a polypeptide having the activity of stimulating IL-2-induced T cell kinase and a function of treating cancers. The polypeptide has a novel sequence, can inhibit colon cancer cells and pancreatic cancer cell proliferation activity, and can inhibit the migration of vascular endothelial cells. An in-vivo test proves that the polypeptide improves a survival rate of tumor-bearing mice and has a potential novel drug development value.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Application of e3 ubiquitin ligase asb3 in the preparation of therapeutic drugs for liver cancer
ActiveCN108949974BInhibition of proliferative activityArrest growth cycleOrganic active ingredientsGenetic material ingredientsTumor targetCancer cell
The invention relates to the field of biomedicine, in particular to the application of E3 ubiquitin ligase ASB3 as a new anti-tumor target in the preparation of drugs for treating liver cancer. The invention provides a new treatment method for liver cancer by specifically down-regulating ASB3 with small interfering RNA. Interfering with ASB3 can inhibit the proliferation of liver cancer cells and induce apoptosis of liver cancer cells; it has a therapeutic effect on subcutaneous liver cancer implantation in nude mice; it solves the technical problems of poor curative effect and poor prognosis of the existing treatment methods for middle and advanced liver cancer.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Hydrolyzed plasminogen polypeptides
InactiveCN105039294AGood curative effectPromote hydrolysisAntineoplastic agentsPeptidasesAbnormal tissue growthAngiostatins
The invention provides hydrolyzed plasminogen polypeptides, relating to the field of drugs, particularly polypeptides capable of promoting hydrolysis of plasminogen into angiostatin and treating malignant tumors. The sequence EMQKTVDRLKALNHFDENMW is a brand-new sequence. The polypeptides are capable of promoting hydrolysis of plasminogen in vitro, inhibiting vessel endotheliocytes from proliferation and enhancing the survival rate of tumor bearing mice in an in-vivo test, and have potential new drug development value.
Owner:顾彩霞
Vascular-endothelial-growth-factor-C antagonistic polypeptide and application thereof
InactiveCN104693285AInhibition of proliferative activityImprove survival ratePeptide/protein ingredientsPeptidesPharmacologyBlood vessel
The invention relates to the field of drugs, in particular to polypeptide for suppressing vascular endothelial growth factors C and treating the acute lymphocytic leukemia. The sequence of the polypeptide is NHISTPQCQGLSKPHKITV and is a brand new sequence. By means of the polypeptide, the vascular endothelial growth factors C can be suppressed out of a body at a 1-micromole level, the tumor-bearing mice survival rate can be increased in an in-vivo test, and the potential new drug development value is achieved.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Perforin chaperonin polypeptide and application thereof
InactiveCN106496319AHigh activityPromote apoptosisPeptide/protein ingredientsAntineoplastic agentsApoptosisOncology
The invention relates to the field of medicine, and particularly relates to a polypeptide which is capable of promoting activity of perforin and treating malignant tumor. Sequences of the polypeptide are brand new sequences, are capable of inhibiting proliferation activities of a hepatoma carcinoma cell and a liver cancer stem cell simultaneously at the same time, and can promote apoptosis of the liver cancer stem cell. In an in-vivo test, a survival rate of a nude mouse bearing the liver cancer and the tumor is improved, and thus the perforin chaperonin polypeptide has potential new drug development value.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Signal transduction and transcriptional activation factor inhibitory polypeptide and application thereof
InactiveCN104725480AInhibition of proliferative activityPrevention and Treatment of RelapsePeptide/protein ingredientsPeptidesIn vivo testsMetastasis
The invention relates to the field of medicines, and in particular relates to a polypeptide provided with an inhibiting signal transduction and transcriptional activation factor and used for preventing and treating cancer recurrence and metastasis after breast cancer. The sequence of the polypeptide is MEQFRHLRANPSWPHLQMFP and is a brand-new sequence, the sequence can be used for in vitro inhibiting proliferation and migration of breast cancer cell, the survival rate of the tumor-bearing mice is improved in an in vivo test, and the polypeptide has potential new medicine development value.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Pharmaceutical composition containing medicinal calcium salt for early preventing colorectal adenoma or colorectal cancer
InactiveCN102085217BInhibit malignant transformationInhibition of proliferative activityInorganic phosphorous active ingredientsDigestive systemOncologyWilms' tumor
The invention discloses a pharmaceutical composition containing medicinal calcium salt for early preventing colorectal adenoma or colorectal cancer. The pharmaceutical composition contains sodium butyrate and medicinal calcium salt, wherein the mass ratio of the sodium butyrate to elemental calcium in the pharmaceutical composition is (2.47-4.95):1. The pharmaceutical composition disclosed by theinvention can reduce cancer genes related to the colorectal cancer and can increase related cancer suppressor genes and signal passages to suppress colorectal cancer cell proliferation and migration capabilities and retard cell growth cycle, thereby achieving the purposes of suppressing the occurrence of the colorectal cancer, lowering the incidence rate of the colorectal cancer of mice, and reducing the tumor volume.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Vascular endothelial growth factor C antagonistic polypeptide and application thereof
InactiveCN104693286AInhibition of proliferative activityImprove survival ratePeptide/protein ingredientsPeptidesAcute lymphocytic leukemiaEndothelium
The invention relates to the field of medicines, in particular to polypeptide for restraining vascular endothelial growth factors C and treating acute lymphocytic leukemia. The sequence of the polypeptide is GPREGPKPLSQCVCKHHQ which is brand new, the polypeptide can restrain the vascular endothelial growth factors C in vitro on the 1 micromole level, the survival rate of tumor-bearing mice in in-vivo tests is improved, and the polypeptide has potential new drug development value.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Antagonistic polypeptide for vascular endothelial growth factor C and application of antagonistic polypeptides
InactiveCN104744565AInhibition of proliferative activityImprove survival ratePeptide/protein ingredientsPeptidesCancer researchBlood vessel
The invention relates to the field of medicines, particularly polypeptides which can be used for inhibiting a vascular endothelial growth factor C and treat acute lymphocytic leukemia. The sequence of the polypeptides is DFMCQCVCNKLFRRP which is a brand new sequence; the polypeptides can be used for in vitro inhibiting the vascular endothelial growth factor C at a one-micromole level and moreover improving the survival rate of tumor-bearing mice in an in vivo test and have a potential new drug development value.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Signal transduction and activating transcription factor inhibiting polypeptide
InactiveCN105037501AImprove survival rateInhibition of proliferative activityPeptide/protein ingredientsPeptidesDrugFactor ii
The invention relates to the field of medicaments, and in particular relates to polypeptides capable of inhibiting signal transduction and activating transcription factors as well as preventing and treating relapse and metabasis of breast cancer after operation. The polypeptides have a brand-new sequence of QLKNLYKDEANPSWPPTEQ and can inhibit the proliferation and migration of breast cancer cells in vitro and improve the survival rate of tumor-bearing mice in in-vivo tests, so that the polypeptides have potential new medicament development value.
Owner:倪勤华
Angiostatin activator polypeptide
InactiveCN105039293APromote prohydrolysisPromote hydrolysisAntineoplastic agentsPeptidasesAngiostatinImproved survival
The invention relates to the field of medicines and in particular relates to a polypeptide capable of activating angiostain and treating malignant tumour. A sequence of the polypeptide is EALALMYYHSQSLRKTYP is brand-new, and the polypeptide can activate angiostain in vitro and inhibit proliferation of vascular endothelial cells and also can improve survival rate of tumour-bearing mice during in-vivo test, so that the polypeptide has potential value in development of new drugs.
Owner:倪勤华
Jaggedl-associated agonist polypeptide and application thereof
InactiveCN104761622AImprove survival rateInhibition of proliferative activityPeptide/protein ingredientsDepsipeptidesIn vitro testLiver cancer
The invention discloses a Jaggedl-associated agonist polypeptide and an application thereof, and relates to the drug field, in particular to a polypeptide for promoting Jaggedl and Notch to combine to treat malignant tumors. A sequence of the Jaggedl-associated agonist polypeptide is NSFTDDCRRSDGHCRRELDPM, and is a brand-new sequence which can be used for restraining proliferation of melanoma cells and liver cancer stem cells in vitro and increasing a survival rate of tumor-bearing mice in an in-vitro test, and has a potential new drug development value.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Application of pectolinarin in preparation of anti-osteosarcoma medicine and anti-osteosarcoma medicine preparation
PendingCN113908168APrevent proliferationInhibit migrationOrganic active ingredientsAntineoplastic agentsCell divisionPharmaceutical drug
The invention discloses application of pectolinarin in preparation of an anti-osteosarcoma medicine and an anti-osteosarcoma medicine preparation, and belongs to the technical field of medicines. In-vivo and in-vitro experiments prove that the pectolinarin can inhibit growth and proliferation of various osteosarcoma cells, can promote apoptosis of the osteosarcoma cells, can intervene the cell cycle, can retard the cells in the G1 stage, can reduce the number of the cells in the G2 stage and can inhibit the cell division ability; the invasion and migration of HOS and 143B osteosarcoma cells can be inhibited; and animal experiments prove that pectolinarin can obviously inhibit the volume of nude mouse subcutaneous 143B cytoma and can well inhibit the growth of osteosarcoma. The pectolinarin is expected to become a medicine for treating osteosarcoma and has a wide prospect in the aspect of development of the medicine for treating osteosarcoma.
Owner:LUOYANG ORTHOPEDIC TRAUMATOLOGICAL HOSPITAL
Jagged1 agonist polypeptide and application thereof
InactiveCN104693278AInhibition of proliferative activityImprove survival ratePeptide/protein ingredientsPeptidesAbnormal tissue growthHuman body
The invention discloses Jagged1 agonist polypeptide and application thereof, and relates to the field of medicines, in particular to polypeptide which can promote combination of Jagged1 and Notch and treats malignant tumor. The sequence is GDDCGTGGTCAAAALLPCVD and is a novel sequence, the Jagged1 agonist polypeptide can suppress proliferation of melanoma cells and liver cancer stem cells outside the human body, and the survival rate of tumor-bearing mice is improved in the intra-body experiment. The Jagged1 agonist polypeptide can serve as a detection kit, and has potential novel medicine development value.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Application of cell cycle regulatory gene fam114a2
ActiveCN107513556BInhibition of proliferative activityIncrease proliferative activityMicrobiological testing/measurementFermentationKidney cancerTumor therapy
The invention discloses the application of the cell cycle regulating gene fam114a2. It is found through research that the gene has a cell cycle regulating effect and inhibits cell proliferation, so it can be used as a cell cycle regulating agent and as a target gene for tumor treatment; and the gene is used in renal cancer , liver cancer, gastric cancer and paracancerous tissues are specifically highly expressed, so it can also be used as a diagnostic marker for renal cancer, liver cancer, and gastric cancer, and is of great significance to the diagnosis and treatment of tumors.
Owner:SOUTHWEST UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com